Weekly Digest – March 2025 Weekly Digest – March 2025 17 Mar 2025: Taiho Pharmaceutical to acquire next-generation ADC drug discovery company Araris Biotech Taiho Pharmaceutical has entered into a definitive agreement to fully acquire Araris Biotech, a swiss biotechnology […]
Weekly Digest – March 2025 Weekly Digest – March 2025 19 Mar 2025: Oxford BioTherapeutics enters into a strategic collaboration with Roche to discover novel targets for antibody-based therapeutics for the treatment of cancer Oxford BioTherapeutics (OBT) has partnered with […]
Weekly Digest – March 2025 Weekly Digest – March 2025 10 Mar 2025: Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) approved for marketing in second indication by NMPA for EGFRm NSCLC • Sichuan Kelun-Biotech’s TROP2-directed ADC, sac-TMT, is now approved in […]
Weekly Digest – March 2025 Weekly Digest – March 2025 12 Mar 2025: Zai Lab announces acceptance of biologics license application for TIVDAK for the treatment of patients with recurrent or metastatic Cervical cancer Zai Lab announced that China’s NMPA […]
Weekly Digest – March 2025 Weekly Digest – March 2025 13 Mar 2025: ImmunoPrecise teases $10M ADC, bispecific collab with major biotech ImmunoPrecise antibodies has partnered with a leading biotech company to develop antibody-drug conjugates and bispecific antibodies for cancer […]
Weekly Digest – March 2025 Weekly Digest – March 2025 13 Mar 2025: SOTIO Expands ADC Pipeline and Synaffix collaboration to develop two novel bispecific candidates, SOT112 and SOT113 SOTIO is exercising its option under the agreement with Synaffix to […]
Weekly Digest – March 2025 Weekly Digest – March 2025 11 Mar 2025: WuXi XDC and AbTis announce strategic partnership to advance next-generation ADCs WuXi XDC, a leading CRDMO in ADCs, signed an MOU with AbTis, a south Korean ADC […]
Weekly Digest – March 2025 Weekly Digest – March 2025 10 Mar 2025: Immunome doses first patient in Phase 1 trial of IM-1021, a ROR1-targeted ADC Immunome, Inc. has initiated the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC, […]
Weekly Digest – March 2025 Weekly Digest – March 2025 05 Mar 2025: Celltrion receives FDA Phase 1 IND approval for next-generation ADC Drug ‘CT-P70’ Celltrion received FDA approval for an Investigational New Drug (IND) application for its antibody-drug conjugate […]
Weekly Digest – March 2025 Weekly Digest – March 2025 28 Feb 2025: Enhertu recommended for approval in the EU by CHMP for patients with HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy Enhertu has been […]
